Benitec Biopharma Releases Full Year 2022 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

California , United States , Canada , France , America , Benitec Biopharma , William Windham , Central Ethics Committee , Clinical Development Program Overview , Benitec Biopharma Inc , Nasdaq , Solebury Strategic Communications , Exchange Commission , Regulatory Updates For The Clinical Development Program , Research Ethics Board , Assay Method Development , Fiscal Year , Executive Chairman , Chief Executive Officer , Oculopharyngeal Muscular Dystrophy , Development Program Overview , Pharyngeal Residue , Maximum Constriction , Imaging Grade , Swallowing Toxicity Scale , Pyriform Sinus Residue , Residue Ratio Scale , Construction Ratio , Treatment Study , Regulatory Updates , Clinical Development Program , Second Calendar Quarter , Patient Informed Consent Form , Principal Investigators , Third Calendar Quarter , Patient Informed Consent , Fourth Calendar Quarter , Institutional Review Board , Trial Application , Investigational New Drug , First Calendar Quarter , Toxicology Study , Parallel Assay Method Development , Comprehensive Loss , Ended June , Relations Contact , Covid 19 , Science , Technology , Health , Muscular Dystrophy , Biotechnology , Hayward , Business , Globe Newswire , Gene Therapy ,